T-1101 OPC approved by the TFDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 IND application has been approved by FDA in Sept, 2016 and further by TFDA in Jan, 2017. T-1101 acts through disrupting the interaction between Hec1 and Nek2, these proteins involved in mitotic regulation that are …
T-1101 OPC approved by the TFDA to start Phase I clinical study Read More »